BEAM invests in CRISPR-based therapeutics
/Beam Brings In $135M to Turn CRISPR Base Editing into Drugs
Xconomy Boston — Beam Therapeutics made a splash last year when it launched with $87 million to develop medicines that use a more precise form of CRISPR editing. Beam’s promise of CRISPR-based therapeutics that swap out specific bases or “letters” in the genome—something the current generation of CRISPR-based drugs can’t do—has been so enticing to investors that they have put in $135 million in a Series B investment less than a year after the first funding round.
